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We thank Hurkmans et al for their interest in our published manuscript. The points they 
raised were 1) not reporting on the volume dependence of the deviation from intended 
target coverage when density corrected is applied, 2) recommended criteria with 
heterogeneity correction are based upon plans that are not optimized with heterogeneity 
correction. We specified in the manuscript the limitation that the density corrected plans 
were not optimized. We agree with Hurkmans et al that this is a very important point to 
present.  The optimized criteria should also include consideration of other important 
factors such as tumor motion management. The recommended criteria were intended to 
be an initial guidance to further investigation to optimize these criteria. We have initiated 
the investigation with the cases from RTOG study 0236 and planed against criteria from 
Xiao et al1 , RTOG 0813 and those from ROSEL study2 . Of the twenty cases we studied, 
we found that these were comparable criteria. Similar cases fulfill or fail either set of 
criteria. Further investigations and fine tuning of the criteria involving more cases from 
an increased number of institutions are warranted to ensure acceptable balance between 
plan quality and accrual for future SBRT lung clinical trials.   
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